Table 3.
Odds ratios for hospitalization due to serious liver injury associated with antidepressant of interest versus selective serotonin reuptake inhibitors (SSRIs) in each case-time-control study performed by antidepressant of interest
| Antidepressant of interest in each case-time-control studya | Cases | Odds ratio (95% CI) | ||
|---|---|---|---|---|
| Reference period (n)b | Risk period (n)c | Crude | Adjustedd | |
| Venlafaxine | 21 | 28 | 1.00 (0.56–1.81) | 0.94 (0.51–1.72) |
| Milnacipran | 5 | 2 | 0.43 (0.08–2.36) | 0.86 (0.12–5.98) |
| Duloxetine | 13 | 18 | 1.09 (0.52–2.30) | 1.15 (0.53–2.53) |
| Mianserin | 16 | 21 | 1.07 (0.54–2.11) | 0.91 (0.42–1.97) |
| Mirtazapine | 11 | 13 | 0.93 (0.40–2.18) | 1.13 (0.43–3.00) |
| Tianeptine | 17 | 7 | 0.94 (0.37–2.36) | 1.06 (0.40–2.82) |
| Agomelatine | 5 | 4 | 0.69 (0.18–2.69) | 0.87 (0.12–6.34) |
CI confidence interval, SSRIs selective serotonin reuptake inhibitors
aEligible profiles in each case-time-control study performed by antidepressant of interest: individuals with reimbursements for both (1) antidepressant of interest in the absence of SSRIs during one of the two periods (i.e., risk or reference) and (2) SSRIs in the absence of antidepressant of interest during the other period
bNumber of cases with reimbursements for both (1) antidepressant of interest in the absence of SSRIs during the reference period and (2) SSRIs in the absence of antidepressant of interest during the risk period
cNumber of cases with reimbursements for both (1) antidepressant of interest in the absence of SSRIs during the risk period and (2) SSRIs in the absence of antidepressant of interest during the reference period
dAdjusted for variations in drugs potentially associated with hepatotoxicity and other antidepressant reimbursement between reference and risk periods